|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM114760446 |
| 003 |
DE-627 |
| 005 |
20231222170702.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0383.xml
|
| 035 |
|
|
|a (DE-627)NLM114760446
|
| 035 |
|
|
|a (NLM)11580231
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Vambutas, A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.12.2001
|
| 500 |
|
|
|a Date Revised 30.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a Human papillomaviruses (HPVs) cause benign and malignant epithelial tumors of the respiratory and genital mucosa. We previously reported that recurrent respiratory papillomas caused by HPV 6/11 express low levels of antibody-detectable TAP-1, the protein that transports peptides into the endoplasmic reticulum for assembly and presentation by MHC Class I, and that the extent of TAP-1 immunostaining is inversely related to the frequency of disease recurrence. We have now determined a mechanism for the reduction in TAP-1 detection. Anti-TAP-1 antibody immunoprecipitated very low amounts of protein from papilloma cells. However, immunoprecipitation of calreticulin, another member of the MHC I assembly complex, coprecipitated TAP-1 at levels comparable to those of uninfected cells. Immunoprecipitation of an HPV-positive cell line with either anti-TAP-1 or anti-calreticulin coprecipitated HPV E7 protein. Finally, purified HPV 11 E7 protein inhibited ATP-dependent peptide transport in vitro. We propose that the interaction of E7 with TAP-1 prevents TAP-1 antibody detection and efficient peptide transport, resulting in poor presentation of viral antigen on HPV-infected cells and thus failure to mount an effective immune-mediated prevention of disease recurrence
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a ATP Binding Cassette Transporter, Subfamily B, Member 2
|2 NLM
|
| 650 |
|
7 |
|a ATP-Binding Cassette Transporters
|2 NLM
|
| 650 |
|
7 |
|a Oncogene Proteins, Viral
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a TAP1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a oncogene protein E7, Human papillomavirus type 6
|2 NLM
|
| 650 |
|
7 |
|a Adenosine Triphosphate
|2 NLM
|
| 650 |
|
7 |
|a 8L70Q75FXE
|2 NLM
|
| 700 |
1 |
|
|a DeVoti, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pinn, W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steinberg, B M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bonagura, V R
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 101(2001), 1 vom: 28. Okt., Seite 94-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:101
|g year:2001
|g number:1
|g day:28
|g month:10
|g pages:94-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 101
|j 2001
|e 1
|b 28
|c 10
|h 94-9
|